Advertisement

Topics

The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.

07:00 EST 23rd February 2018 | BioPortfolio

Summary of "The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data."

Recurrent hepatitis C (RHC) in orthotopic liver transplantation (OLT) population is associated with accelerated rates of fibrosis, low efficacy and decreased tolerability with traditional therapies.

Affiliation

Journal Details

This article was published in the following journal.

Name: European journal of gastroenterology & hepatology
ISSN: 1473-5687
Pages:

Links

DeepDyve research library

PubMed Articles [23652 Associated PubMed Articles listed on BioPortfolio]

Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.

Currently, there are no interferon-free treatments available for HCV-infected patients younger than 12 years of age. We evaluated the safety and effectiveness of the all-oral regimen ledipasvir-sofosb...

Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.

Approximately 10%-15% of patients with hepatitis C genotype 1 (HCV GT1) experience virological relapse after all-oral antiviral regimen using simeprevir (SMV) and sofosbuvir (SOF). The efficacy and sa...

Real Life Efficacy of Ledipasvir/Sofosbuvir in Hepatitis C Genotype 4-infected Patients with Advanced Liver Fibrosis and Decompensated Cirrhosis.

Limited clinical trial data has shown high efficacy of co-formulated ledipasvir/sofosbuvir (LDV/SOF) in the treatment of hepatitis C virus (HCV) genotype (GT)-4 infected cirrhotic patients. We assesse...

Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.

Clinical studies evaluating the efficacy of daclatasvir (DCV) for treatment of chronic hepatitis C virus (HCV) genotype 4 (GT4) infection are scarce. This study aims to evaluate the efficacy and safet...

Sustained Viral Response in Genotype 4 Chronic HCV Infected Children and Adolescents Treated with Sofosbuvir/Ledipasvir.

Recently, direct acting antivirals (DAAs), sofosbuvir (SOF) combined with ledipasvir (LED) were approved for treatment of HCV infected children 12 years of age and older or weighting at least 35 kg ...

Clinical Trials [13066 Associated Clinical Trials listed on BioPortfolio]

Sofosbuvir+Ledipasvir ±Ribavirin and Sofosbuvir+Ribavirin for Pts With Indolent Bcell Lymphoma Associated With HCV Infection Treatment With Sofosbuvir Plus Ledipasvir ± Ribavirin(G1, 3 and 4) and Sofosbuvir+Ribavirin(G2) for Pts With Hepatitis C Virus A

This is a non-randomized, a single arm, phase II multicentre study of sofosbuvir plus ledipasvir ± ribavirin (genotype 1, 3 and 4) or sofosbuvir + ribavirin (genotype 2) for patients with...

12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF

People who are infected with Hepatitis C Virus (HCV) have a great chance of being cured of the infection when they are treated with sofosbuvir. However, in some instances, treatment with s...

LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients

Evaluate the proportion of patients with HCV viral replication with fixed dose combination of ledipasvir and sofosbuvir for 8 weeks and 12 weeks when initiated within the first 90 days ...

Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

This study will evaluate the efficacy, safety and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) for 12 weeks with or without ribavirin (RBV) in participants ...

Sofosbuvir, Ledipasvir, Ribavirin for HCV Cirrhotics, Genotype 1

The investigators will treat 50 patients with cirrhosis due to hepatitis C genotype 1, with sofosbuvir 400 mg daily, ledipasvir 90 mg daily and weight-based ribavirin (1000 mg/d if 75 kg, divide...

Medical and Biotech [MESH] Definitions

Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, practicability, etc., of these interventions in individual cases or series.

A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.

The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.

Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.

The testing of materials and devices, especially those used for PROSTHESES AND IMPLANTS; SUTURES; TISSUE ADHESIVES; etc., for hardness, strength, durability, safety, efficacy, and biocompatibility.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topic

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...


Searches Linking to this Article